Jason Westin, MD, FACP, University of Texas MD Anderson Center, Houston, TX, talks on the rationale and design of the LOTIS-9 study, a Phase II study assessing the efficacy and tolerability of the combination of loncastuximab tesirine (Lonca-T) and rituximab in unfit and frail patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) (NCT05144009). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.